| Breast Cancer |
1 |
1 |
| HER2-Positive Breast Cancer |
0 |
0.68 |
| Triple Negative Breast Cancer |
0 |
0.68 |
| Cancer |
0 |
0.63 |
| Biologic Therapy |
0 |
0.6 |
| Antineoplastic Drug |
0 |
0.57 |
| Breast |
0 |
0.51 |
| Cancer Risk |
0 |
0.47 |
| Ovarian Cancer |
0 |
0.47 |
| Toxicology |
0 |
0.43 |
| Genomic Medicine |
0 |
0.4 |
| Chemotherapy |
0 |
0.39 |
| Adjuvant Chemotherapy |
0 |
0.36 |
| Gynecologic Surgery |
0 |
0.23 |
| Surgery |
0 |
0.18 |
| Anthracyclines |
0 |
0.15 |
| Humanized Monoclonal Antibody |
0 |
0.12 |
| Hysterectomy |
0 |
0.12 |
| Clinical Research |
0 |
0.09 |
| Estrogen |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Hormone Replacement Therapy |
0 |
0.09 |
| Oophorectomy |
0 |
0.09 |